Tandem Diabetes Care, Inc. (TNDM) has witnessed strong momentum in the past year. Shares of the company have risen 45.7% compared with the industry’s 7.3% growth during the same time frame. The S&P 500 composite has increased 24.7%.With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.Tandem Diabetes Care, Inc. designs, develops and markets products for people with insulin-dependent diabetes. Its flag ...

Tandem Diabetes Care, Inc.’s (TNDM) impressive strategic initiatives are expected to bolster growth in the upcoming quarters. A robust diabetes market provides a favorable opportunity for the company’s growth. However, concerns loom over the adverse impact of macroeconomic challenges. Moreover, the company’s heavy dependence on insulin pumps is worrisome. In the past year, this Zacks Rank #3 (Hold) company’s shares have surged 44.8% compared with 7.3% growth of the industry and a 24.7% rise of the S&P 500 c ...

Tandem Diabetes Care, Inc. (TNDM) has signed a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology (UVA). The partnership will focus on advancing research and development efforts on fully automated closed-loop insulin delivery systems.Tandem Diabetes’ previous work with UVA, including research related to its automated insulin delivery systems as part of the International Diabetes Closed Loop trials, has resulted in life-changing products for the diabetes communi ...

Tandem Diabetes Care, Inc. (TNDM) announced that the in-warranty users of the t:slim X2 insulin pump in Canada can now access full compatibility with both Dexcom’s (DXCM) G7 and G6 Continuous Glucose Monitoring (“CGM”) systems. This follows Health Canada’s sale authorization in July 2024, making t:slim X2 with Control-IQ technology the first and only insulin pump in Canada to be integrated with both systems.The commercial availability of this new offering reflects the decade-long partnership between the two ...

Tandem Diabetes Care, Inc. (TNDM) posted a third-quarter 2024 loss of 36 cents per share compared with the year-ago quarter’s reported loss of 38 cents. The figure beat the Zacks Consensus Estimate of a loss of 43 cents per share.On a GAAP basis, the loss was 35 cents per share compared with the year-ago loss of 51 cents.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the earnings announcement, TNDM stock fell 2% in aftermarket trading yesterday. TNDM’s Q3 RevenuesGAAP reven ...

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Susan Morrison - EVP and Chief Administrative Officer. John Sheridan - President and CEO Leigh Vosseller - EVP and CFO Conference Call Participants Mathew Blackman - Stifel Steve Lichtman - Oppenheimer & Company Brooks O'Neil - Lake Street Capital Markets Matt Miksic - Barclays Larry Biegelsen - Wells Fargo Matthew O'Brien - Piper Sandler Patrick Wood - Morgan Stanley Matt Taylor - Jeff ...

For the quarter ended September 2024, Tandem Diabetes Care, Inc. (TNDM) reported revenue of $243.97 million, up 31.4% over the same period last year. EPS came in at -$0.36, compared to -$0.38 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $223.33 million, representing a surprise of +9.24%. The company delivered an EPS surprise of +16.28%, with the consensus EPS estimate being -$0.43.While investors closely watch year-over-year changes in headline numbers -- revenue ...

Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.28%. A quarter ago, it was expected that this company would post a loss of $0.54 per share when it actually produced a loss of $0.47, delivering a surprise of 12.96%.Over the last four quarters, the company h ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________________________ FORM 10-Q _____________________________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the T ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Third Quarter 2024 Highlights Media Contact: 858-366-6900 media@tandemdiabetes.com Investor Contact: 858-366-6900 IR@tandemdiabetes.com Tandem Diabetes Care Announces Third Quarter 2024 Financial Results and Increases Full Year 2024 Sales Guidance San Diego, November 6, 2024 - Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2024 and increased sales ...